Evolutionary Therapy for Rhabdomyosarcoma (NCT04388839)
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The participant and their physician will choose from: Arm A) a first strike therapy, Arm B) a first strike-second strike (maintenance) therapy, Arm C) an adaptively timed therapy, and Arm D) conventional chemotherapy.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama
- Children's Hospital of Colorado — Aurora, Colorado
- Connecticut Children's Medical Center — Hartford, Connecticut
- University of Florida — Gainesville, Florida
- University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
- Johns Hopkins All Children's Hospital — St. Petersburg, Florida
- Moffitt Cancer Center — Tampa, Florida
- Roswell Park Comprehensive Cancer Center — Buffalo, New York
- Montefiore Medical Cancer Center — The Bronx, New York
- University of North Carolina Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Carolinas Medical Center, Levine Cancer Institute — Charlotte, North Carolina
- Duke Children's Hospital — Durham, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
- Vanderbilt - Ingram Cancer Center — Nashville, Tennessee
- University of Texas Southwestern Medical Center — Dallas, Texas
- MD Anderson — Houston, Texas
- Primary Children's Medical Center/Utah — Salt Lake City, Utah
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Rhabdomyosarcoma
- Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy — Jacksonville, Florida
- Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma — Los Angeles, California
- Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials — San Francisco, California
- Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) — Washington D.C., District of Columbia
- FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma — Bethesda, Maryland
Explore by condition: All Rhabdomyosarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.